Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 1/20 | 0.43 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.43 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.43 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.43 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.43 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220177 | 0.95 | CACNB4 (0.41) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL4291063 | 0.93 | PIK3CD (0.46) | PDE4BMEN1KMT2ANOS1NOS3 | |
| SCHEMBL4898636 | 0.90 | CACNB4 (0.39) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15122119 | 0.90 | NOS3 (0.51) | PDE4BMEN1KMT2ANOS1NOS3 | |
| SCHEMBL6583260 | 0.87 | NOS1 (0.42) | MEN1KMT2ANOS1NOS3NOS2 | |
| SCHEMBL8471365 | 0.84 | NOS1 (0.51) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL421347 | 0.82 | NOS1 (0.48) | NOS1NOS3NOS2 | |
| SCHEMBL424370 | 0.82 | NOS1 (0.54) | MEN1KMT2ANOS1NOS3NOS2 | |
| SCHEMBL3314495 | 0.81 | PDE4B (0.48) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL221708 | 0.80 | NOS1 (0.45) | MEN1KMT2ANOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | CACNB4 98/4885CACNA1A 51/4885CACNA1G 44/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | CACNB4 2986/4885CACNA1A 2560/4885CACNA1G 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.